{"genes":["EGFR","MAPK","BRAF V600E mutant allele","RAS"],"organisms":["6755"],"publicationTypes":["Journal Article"],"abstract":"Findings from a phase I/II study indicate a higher response rate among patients with BRAF-mutant metastatic colorectal cancer treated with an EGFR inhibitor alongside dual, as opposed to single-level, MAPK blockade. Panitumumab combined with trametinib and dabrafenib only modestly increased median progression-free survival, however; a short-lived decrease in responders\u0027 BRAF V600E mutant allele fraction and the emergence of RAS mutations may have been contributing factors.","title":"Triple Therapy Improves Colorectal Cancer Response.","pubmedId":"27770002"}